Delineating the clinical and molecular heterogeneity of fatty liver disease to inform treatment [ 1/1/2021 - 12/31/2025 ]

Research Grant

Brief description Fatty liver disease from excess weight affects 1 in 3 adult Australians. The disease has no treatments and many patients develop liver failure or liver cancer. Clinically, the disease is characterized by marked heterogeneity, a challenge for developing biomarkers and treatments. To move towards precision medicine, this project will undertake an inter-disciplinary program that embraces disease complexity and integrates environmental and genetic risk with the power of mathematical modelling.

Funding Amount $1,731,372

Funding Scheme Investigator Grants

Chief Investigator Prof Jacob George

Notes Leadership 3